Docs Who Lift
FLOW trial and GLP-1 cost rant
Jun 4, 2024
Drs. Karl and Spencer discuss the FLOW trial showing kidney protection with semaglutide, rant about costly medicines, compounding considerations, and the need for heart and kidney health focus in diabetes management.
45:30
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Semaglutide in the FLOW trial showed kidney protective effects.
- The podcast emphasizes the importance of diabetes medications in kidney protection.
Deep dives
Overview of the Flow Trial and Renal Outcomes
The podcast discusses the Flow Trial using Ozempic at one milligram and its findings on kidney outcomes, indicating its kidney protective effects. It highlights the increased risks of heart and kidney diseases associated with obesity and diabetes, emphasizing the significance of cardioreno focus in managing these complications.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
